Kevin DeGeeter
Stock Analyst at Oppenheimer
(0.54)
# 3,770
Out of 4,789 analysts
43
Total ratings
28.57%
Success rate
-23.61%
Average return
Main Sectors:
Stocks Rated by Kevin DeGeeter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANTX AN2 Therapeutics | Initiates: Outperform | $22 | $1.36 | +1,517.65% | 1 | Apr 19, 2022 | |
| ORIC ORIC Pharmaceuticals | Downgrades: Perform | n/a | $5.58 | - | 1 | Mar 22, 2022 | |
| PSNL Personalis | Maintains: Outperform | $30 → $24 | $3.51 | +583.76% | 4 | Feb 25, 2022 | |
| NVCR NovoCure | Upgrades: Outperform | $98 | $17.82 | +449.94% | 3 | Feb 2, 2022 | |
| FLGT Fulgent Genetics | Maintains: Outperform | $141 → $125 | $16.90 | +639.64% | 3 | Jan 25, 2022 | |
| MDXH MDxHealth | Initiates: Outperform | $18 | $1.42 | +1,167.61% | 1 | Nov 29, 2021 | |
| SERA Sera Prognostics | Initiates: Outperform | $19 | $3.68 | +416.30% | 1 | Nov 19, 2021 | |
| SPRO Spero Therapeutics | Downgrades: Perform | n/a | $0.72 | - | 1 | Oct 1, 2021 | |
| PRTG Portage Biotech | Initiates: Outperform | $600 | $9.25 | +6,386.49% | 1 | Sep 21, 2021 | |
| PANW Palo Alto Networks | Maintains: Outperform | $75 → $79 | $170.64 | -53.60% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $161 → $155 | $43.29 | +258.05% | 2 | Jul 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $0.39 | - | 2 | Jun 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $2.90 | +762.07% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $255 | $0.28 | +91,232.38% | 1 | Apr 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $1,800 | $1.85 | +97,197.30% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $44.62 | - | 2 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.39 | - | 1 | Jan 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $6.67 | - | 4 | Dec 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $0.32 | +15,757.91% | 1 | Jul 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $2.79 | +32,158.06% | 1 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $6.41 | - | 2 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $225 | $21.54 | +944.57% | 1 | Apr 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $8.87 | - | 5 | Feb 8, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $2.69 | - | 2 | Jan 4, 2017 |
AN2 Therapeutics
Apr 19, 2022
Initiates: Outperform
Price Target: $22
Current: $1.36
Upside: +1,517.65%
ORIC Pharmaceuticals
Mar 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $5.58
Upside: -
Personalis
Feb 25, 2022
Maintains: Outperform
Price Target: $30 → $24
Current: $3.51
Upside: +583.76%
NovoCure
Feb 2, 2022
Upgrades: Outperform
Price Target: $98
Current: $17.82
Upside: +449.94%
Fulgent Genetics
Jan 25, 2022
Maintains: Outperform
Price Target: $141 → $125
Current: $16.90
Upside: +639.64%
MDxHealth
Nov 29, 2021
Initiates: Outperform
Price Target: $18
Current: $1.42
Upside: +1,167.61%
Sera Prognostics
Nov 19, 2021
Initiates: Outperform
Price Target: $19
Current: $3.68
Upside: +416.30%
Spero Therapeutics
Oct 1, 2021
Downgrades: Perform
Price Target: n/a
Current: $0.72
Upside: -
Portage Biotech
Sep 21, 2021
Initiates: Outperform
Price Target: $600
Current: $9.25
Upside: +6,386.49%
Palo Alto Networks
Aug 24, 2021
Maintains: Outperform
Price Target: $75 → $79
Current: $170.64
Upside: -53.60%
Jul 29, 2021
Maintains: Outperform
Price Target: $161 → $155
Current: $43.29
Upside: +258.05%
Jun 29, 2021
Downgrades: Perform
Price Target: n/a
Current: $0.39
Upside: -
May 27, 2021
Initiates: Outperform
Price Target: $25
Current: $2.90
Upside: +762.07%
Apr 30, 2021
Initiates: Outperform
Price Target: $255
Current: $0.28
Upside: +91,232.38%
Mar 2, 2021
Initiates: Outperform
Price Target: $1,800
Current: $1.85
Upside: +97,197.30%
Jan 11, 2021
Downgrades: Perform
Price Target: n/a
Current: $44.62
Upside: -
Jan 5, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.39
Upside: -
Dec 8, 2020
Downgrades: Perform
Price Target: n/a
Current: $6.67
Upside: -
Jul 1, 2020
Initiates: Outperform
Price Target: $50
Current: $0.32
Upside: +15,757.91%
Apr 8, 2020
Initiates: Outperform
Price Target: $900
Current: $2.79
Upside: +32,158.06%
Aug 9, 2017
Upgrades: Buy
Price Target: n/a
Current: $6.41
Upside: -
Apr 12, 2017
Initiates: Buy
Price Target: $225
Current: $21.54
Upside: +944.57%
Feb 8, 2017
Upgrades: Neutral
Price Target: n/a
Current: $8.87
Upside: -
Jan 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $2.69
Upside: -